Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on AbbVie (NYSE:ABBV) in the last three months. The table below provides a concise overview of ...

AbbVie Inc. (NYSE:ABBV) entered the obesity race last week when it in-licensed GUB014295 (also called GUBamy) from Denmark-based Gubra. The candidate is a long-acting amylin analog for the ...

AbbVie shares recently rebounded, supported by strong earnings, positive guidance, and a late 2024 dividend increase, indicating the potential for further gains. Despite a $3.5 billion impairment ...

AbbVie has filed with the FDA to extend the ... limited to people with depression as well as suicidal ideation and behaviour. Spravato was held up as a potential blockbuster at one point, but ...

AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...

AbbVie is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of its May 2025 meeting, fostering investor attention. Despite reporting a Q4 net ...

AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...

For the full fiscal 2024, AbbVie is expected to deliver an adjusted EPS of $10.06, down 9.5% from $11.11 in fiscal 2023. While in fiscal 2025, its earnings are expected to rebound 21.6% year-over ...

Healthcare & Pharmaceuticalscategory· February 7, 2025 US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections AbbVie said on Friday that the U.S. Food and Drug Administration ...